The US FDA has granted approval for upadacitinib, an oral reversible JAK inhibitor with higher potency for JAK1 (Figure 3b), available in 15 mg and 30 mg doses, as well as Abrocitinib, a selective JAK1 inhibitor (Figure 3b) available in 100 mg and 200 mg doses, for the treatment of AD. The gene discussed is JAK1; the disease is Alzheimer disease.